Samsara BioCapital, LLC: SPYGLASS PHARMA INC (SGP): Quarterly 13F Position History
As of Q2 2026, Samsara BioCapital, LLC reported 2,109,953 shares of SPYGLASS PHARMA INC (SGP), worth $47.0M and representing 3.9% of its 13F equity book. The position first appeared in Q1 2026 and has been disclosed across 2 13F-HR filings in Pactolio's tracked window.
- 2,109,953Shares Held (Latest Filing)
- $47.0MReported Market Value (Latest Filing)
- 3.9%Portfolio Weight (% of 13F Equity Book)
- 0Quarter-over-Quarter Share Change
- -$7.7MQuarter-over-Quarter Value Change
- 2,109,953Peak Reported Shares (Historical)
Recent initiation: Samsara BioCapital, LLC first reported SGP on the Q1 2026 filing, so fewer than three quarters of history are available.
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 2 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q2 2026 | 2,109,953 | 0 | – | $47.0M | 3.9% | $22.3 |
| Q1 2026 | 2,109,953 | – | – | $54.7M | 5.3% | $25.9 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares, a quarter-end mark rather than the manager's cost basis. See the full methodology document for the normalization rules.
When did Samsara BioCapital, LLC first disclose a SGP position in 13F-HR filings?
Samsara BioCapital, LLC first reported SPYGLASS PHARMA INC (SGP) on its 13F-HR filing for the period ending 2026-03-31 (Q1 2026). The position has appeared on 2 reported quarters within Pactolio's tracked window.
What was Samsara BioCapital, LLC's most recent quarter-over-quarter share-count change in SGP?
Samsara BioCapital, LLC held the same 2,109,953 shares of SGP between Q1 2026 and Q2 2026, so the reported share count was unchanged quarter-over-quarter.
Does the implied price-per-share represent Samsara BioCapital, LLC's cost basis in SGP?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.